Glenview Trust’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Glenview Trust’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,575	Closed	-$213K	–	324
2018 Q3	$213K	Buy	+3,575	New	+$209K	0.01%	314
2018 Q2	–	Sell	-7,660	Closed	-$377K	–	327
2018 Q1	$377K	Hold	7,660	–	–	0.03%	261
2017 Q4	$361K	Hold	7,660	–	–	0.02%	268
2017 Q3	$382K	Hold	7,660	–	–	0.03%	254
2017 Q2	$350K	Hold	7,660	–	–	0.03%	247
2017 Q1	$324K	Buy	7,660 +1,170	+18%	+$49K	0.03%	255
2016 Q4	$252K	Buy	+6,490	New	+$262K	0.02%	277

Other funds holding PBE

ACM

Arlington Capital Management Arlington Heights, Illinois $177M AUM 44.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Glenview Trust's PBE Position: Q4 2018 in Review

Glenview Trust sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2018, closing a stake of 3,575 shares — an estimated $213K sold.

Glenview Trust first reported a position in PBE in Q4 2016 and held it in 7 quarters. The position peaked at $382K in Q3 2017. 71 funds tracked by Wall St. Rank hold PBE as of Q4 2018.

Glenview Trust reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2018 after selling out during the quarter.
Glenview Trust sold 3,575 Invesco Biotechnology & Genome ETF shares in Q4 2018, an estimated $213K.
Glenview Trust first reported a position in Invesco Biotechnology & Genome ETF in Q4 2016 and held it in 7 quarters.
Glenview Trust's Invesco Biotechnology & Genome ETF position peaked at $382K in Q3 2017.
71 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2018.

Based on Glenview Trust's 13F filing for Q4 2018, filed 14 Feb 2019.